Oesophageal CarcinomaDELOGASTNCT03246516
Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers
A study testing Questionnaire in people with Oesophageal Carcinoma and Gastric Adenocarcinoma, run by University Hospital, Lille at 10 sites in France.
Trial summary
This study evaluates the role of socioeconomic and individual factors in the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) in oeso-gastric cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Oesophageal Carcinoma, Gastric Adenocarcinoma
- What is being tested?
- Questionnaire
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 258 participants
- Where
- 10 sitesFrance
- Study dates
- 1 Feb 2017to 7 Feb 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age ≥ 18 years
- oesophageal, oeso-gastric junction or gastric cancer non treated cancer
- patient informed of his diagnosis
- speak fluent french
Who cannot join
- history of cancer
- psychological history
- patient under guardianship-
- fortuitous diagnosis of cancer
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
France10 sites
Centre hospitalier de Béthune
Béthune
Centre Hospitalier de Boulogne sur mer
Boulogne-sur-Mer
Centre hospitalier de Calais
Calais
centre Léonard de Vinci
Dechy
Centre d 'oncologie Dunkerquois
Dunkirk
CHRU, Hôpital Claude Huriez
Lille, 59037
Centre oscar Lambret
Lille
Centre hospitalier de Roubaix
Roubaix
Centre Hospitalier de Seclin
Seclin
Centre hospitalier de valenciennes
Valenciennes
About this study
Official title: Individual and Socio-economic Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers
This study evaluates the role of socioeconomic and individual factors in the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) in oeso-gastric cancer.
Read the detailed description
Reducing the time between the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) is essential to improve the vital prognosis and quality of life of patients. Recent data suggest that some sociocognitive and emotional determinants may explain patient delay from a complementary point of view. The main objective of this study is to assess whether, in oeso-gastric cancer, patient delay is linked to these sociocognitive and emotional factors, in addition to previously known factors.
We intend to include in this study 300 patients with a not yet treated oeso-gastric cancer diagnosed in one of 10 health centres in the North of France region. The collected data will be analysed to underline the differences between patients who consulted a doctor earlier versus those who consulted later with a cut off at 8 weeks.
- Conditions
- Oesophageal Carcinoma, Gastric Adenocarcinoma
- Being tested
- Questionnaire
- Medical subject headings
- Esophageal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
Auto and hetero questionnaires:
- STAI Y B, State-Trait Anxiety Inventoriage
- Brief COPE
- RHHI-24, Revised Health Hardiness Inventory
- IPQ-R, Illness Perception Questionnaire
| Study group | Role | What they receive |
|---|---|---|
| Questionnaire | Experimental | Auto and hetero questionnaire Receives: Other: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time limit of first doctor consultation
Median time between date of symptoms appearance and date of first consultation
Measured: baseline
Secondary outcomes (6)
Time limit of system of care
Median time between date of he beginning of clinical investigations and the beginning of treatment
Measured: baseline
cTNM Stage
Stage TNM by distinguishing the early stages (I, II) vs. (III, IV)
Measured: baseline
clinical variables (i.e medical history, symptoms, entry into care pathway)
clinical variables associated with time of first doctor consultation
Measured: baseline
Socio-cognitive variables
Socio-cognitive variables associated with time of first doctor consultation
Measured: baseline
Emotional variables
Emotional variables associated with time of first doctor consultation
Measured: baseline
Survival
Measured: At 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2017
- Study start1 Feb 2017
- Primary completion7 Feb 2025
- Study completion7 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oesophageal CarcinomaStudies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 258 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Collaborators
- University of Lille Nord de France
- Responsible party
- Sponsor
- Investigators
- Guillaume Piessen, MD, PhD, Principal investigator, University Hospital, Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03246516
- Sponsor's protocol ID
- 2015_74
- Other IDs
- 2015-A01986-43
- Acronym
- DELOGAST
- Status last verified
- Dec 2025
- First submitted
- 8 Aug 2017
- Last updated
- 23 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Individual and Socio-economic Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers
- ClinicalTrials.gov ID
- NCT03246516
- Acronym / sponsor ID
- DELOGAST / 2015_74
- Conditions
- Oesophageal Carcinoma, Gastric Adenocarcinoma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 258 participants (actual)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Collaborators
- University of Lille Nord de France
- Study start
- 1 Feb 2017 (actual)
- Primary completion
- 7 Feb 2025 (actual)
- Study completion
- 7 Feb 2025 (actual)
- First posted
- 11 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the role of socioeconomic and individual factors in the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) in oeso-gastric cancer.
Detailed description
Reducing the time between the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) is essential to improve the vital prognosis and quality of life of patients. Recent data suggest that some sociocognitive and emotional determinants may explain patient delay from a complementary point of view. The main objective of this study is to assess whether, in oeso-gastric cancer, patient delay is linked to these sociocognitive and emotional factors, in addition to previously known factors.
We intend to include in this study 300 patients with a not yet treated oeso-gastric cancer diagnosed in one of 10 health centres in the North of France region. The collected data will be analysed to underline the differences between patients who consulted a doctor earlier versus those who consulted later with a cut off at 8 weeks.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Questionnaire | Experimental | Other: QuestionnaireAuto and hetero questionnaire |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- age ≥ 18 years
- oesophageal, oeso-gastric junction or gastric cancer non treated cancer
- patient informed of his diagnosis
- speak fluent french
Key exclusion criteria (4 listed)
- history of cancer
- psychological history
- patient under guardianship-
- fortuitous diagnosis of cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireAuto and hetero questionnaires: * STAI Y B, State-Trait Anxiety Inventoriage * Brief COPE * RHHI-24, Revised Health Hardiness Inventory * IPQ-R, Illness Perception Questionnaire | Other | Questionnaire |
Primary outcome
Time limit of first doctor consultation
Time frame: baseline
Median time between date of symptoms appearance and date of first consultation
6 secondary outcomes
Time limit of system of care
Time frame: baseline
cTNM Stage
Time frame: baseline
clinical variables (i.e medical history, symptoms, entry into care pathway)
Time frame: baseline
Socio-cognitive variables
Time frame: baseline
Emotional variables
Time frame: baseline
Survival
Time frame: At 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Oesophageal Carcinoma
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingObservational study
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Guillaume Piessen, MD, PhD principal investigator
University Hospital, Lille
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Questionnaire in people with Oesophageal Carcinoma and Gastric Adenocarcinoma, run by University Hospital, Lille at 10 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time limit of first doctor consultation (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2025.